Adaptimmune Therapeutics Receives a New Rating from Top Analyst

By Jason Carr

Cowen & Co. analyst Eric Schmidt reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP) today. The company’s shares opened today at $5.21.

Schmidt observed:

“Adaptimmune reported updated data from its Phase II trial of NY-ESO SPEAR T cells.”

According to TipRanks.com, Schmidt is a top 100 analyst with an average return of 25.9% and a 55.1% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Merrimack Pharmaceuticals, and Threshold Pharmaceuticals.

Adaptimmune Therapeutics has an analyst consensus of Moderate Buy.

The company has a one year high of $11.05 and a one year low of $3.76. Currently, Adaptimmune Therapeutics has an average volume of 295K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adaptimmune Therapeutics Plc is a clinical stage biopharmaceutical company, which focuses on novel cancer immunotherapy products based on T-cell receptor platform. Its TCR platform targets NY-ESO-1 cancer antigen. The company was founded in December 2014 and is headquartered in Oxford, the United Kingdom.